HeZhongfang granules

HeZhongfang granules is a Traditional Chinese Medicine (TCM) formulation developed by the Hospital of Chengdu University of Traditional Chinese Medicine. It is primarily investigated as an adjuvant therapy for patients with unresectable locally advanced, recurrent, or metastatic colorectal adenocarcinoma. In clinical trials, such as ChiCTR2100041643, it is evaluated in combination with standard chemotherapy (e.g., FOLFOX, FOLFIRI) and molecular targeted therapies (e.g., bevacizumab, cetuximab) to assess its impact on progression-free survival, objective response rate, and quality of life. The formulation is intended to harmonize the body's internal environment and potentially enhance the anti-tumor effects of conventional treatments while mitigating their associated toxicities.

Other names

HeZhongfang